Search

Search Results

• Parallel Organizational and Technology Innovation: Designing Organizations following SOA Principles

  5-19

  György Bögel

  Peter Krauth

  Views:

  205

  Technology development in general and trends and developments in infocommunication technologies in particular have a direct effect on corporate organizational processes. In information system design, Service Oriented Architecture (SOA) provides a set of principles and methodologies for designing software in the form of interoperable services with defined business functionalities. These loosely coupled components can be reused for different purposes, and can be combined with services bought from outside partners and other service providers. The goal of this study is to describe how SOA principles and
  methods can be used for designing business organizations, i.e. socio-technical systems with human and machine components. Part one is a general overview of SOA as it is used in IT, part two explains how IT systems converge with corporate organizations, and part three presents a model for an organization designed and managed following SOA principles. The research project behind this article was initiated by the Hungarian Post.

  Journal of Economic Literature (JEL) classifications: L14, L22, L86, M15

• The macroeconomic possibilities of biosimilars in developed countries

  3-18

  Peter Halmosi

  Views:

  213

  Biosimilars have been used for the treatment of chronic diseases since 2006 in the EU but only since 2015 in the U.S. Despite high market potentials and presumed positive macroeconomic effects in the health care sector, widespread usage is strongly confronted with the opposition of physicians and pharmacists. However, biosimilars are supposed to reform health care financing, alter market positions of pharmaceutical companies and amend informational triangle among physicians, patients and insurance companies in the near future. The use of biosimilars is supposed by experts to reach extra health related savings even if doctors and pharmacists are averse to offer these products to patients in a certain therapeutic area. Governments have currently found no unique way of regulating the marketing, substitution and price regulation of biosimilars. The aim of this study is to discuss the macroeconomic possibilities and barriers incarnated in the usage of biosimilars in developed countries.

  Journal of Economic Literature (JEL) codes: H51, I11, I12, J18